Topoisomerase 2 Expression and Acute Myeloid Leukemia (AML)
The study conducted by SWOG Cancer Research Network focuses on the expression of Topoisomerase 2 in patients with acute myeloid leukemia (AML). Given the prevalence of AML and the potential for TOP2 as a biomarker for treatment response and prognosis, this research could inform future therapeutic strategies and companion diagnostics. The findings may enhance the competitive positioning of companies developing TOP2 inhibitors or related therapies, as well as provide insights for personalized medicine approaches in AML. The market for AML treatments is significant, with ongoing advancements in targeted therapies and immunotherapies. Companies should consider the implications of these findings in their drug development pipelines and potential collaborations with research networks.
Indication: Leukemia
Modality: gene therapy
Target: Topoisomerase 2 (TOP2)
Sponsor: SWOG Cancer Research Network
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 17, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Topoisomerase 2 (TOP2)
View original source fields
Condition raw: Leukemia
Condition normalized: Leukemia
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: Topoisomerase 2 (TOP2)
Target normalized: Topoisomerase 2 (TOP2)